Skip to main content

Table 4 Univariate analyses of disease-free survival and overall survival

From: Characterization of tumor-infiltrating lymphocytes and their spatial distribution in triple-negative breast cancer

Variables

Category

Disease-free survival

Overall survival

HR (95% CI)

p value

HR (95% CI)

p value

Age

< 50 yrs vs. ≥50 yrs

0.775 (0.335–1.792)

0.552

0.964 (0.359–2.588)

0.941

Histologic type

IC-NST vs. othersa

1.609 (0.478–5.416)

0.443

0.697 (0.092–5.281)

0.727

T stage

T1-2 vs. T3-4

3.386 (1.003–11.436)

0.049

1.513 (0.199–11.500)

0.689

N stage

N0 vs. N1-3

1.935 (0.837–4.473)

0.123

1.759 (0.639–4.843)

0.274

LVI

Absent vs. Present

3.643 (1.544–8.595)

0.003

3.054 (1.109–8.407)

0.031

Histologic grade

II vs. III

1.015 (0.238–4.329)

0.984

1.494 (0.197–11.316)

0.697

DCIS

Absent vs. Present

3.005 (0.892–10.120)

0.076

1.395 (0.449–4.338)

0.565

Tumor border

Pushing vs. Infiltrative

0.885 (0.375–2.089)

0.781

1.740 (0.652–4.645)

0.269

Multicentricity

Absent vs. Present

1.482 (0.550–3.993)

0.437

1.718 (0.554–5.328)

0.349

TIL

< 10% vs. ≥10%

0.387 (0.171–0.878)

0.023

0.693 (0.252–1.911)

0.479

CD4+ TIL

Low vs. High

0.258 (0.096–0.696)

0.007

0.439 (0.152–1.263)

0.127

CD8+ TIL

Low vs. High

0.266 (0.099–0.716)

0.009

0.587 (0.213–1.617)

0.303

CD56+ TIL

Low vs. High

0.328 (0.129–0.833)

0.019

0.578 (0.210–1.592)

0.289

CD57+ TIL

Low vs. High

0.416 (0.171–1.012)

0.053

0.593 (0.215–1.631)

0.311

GNLY+ TIL

Low vs. High

0.401 (0.165–0.976)

0.044

0.563 (0.204–1.551)

0.266

GZMB+ TIL

Low vs. High

0.621 (0.269–1.436)

0.266

0.985 (0.370–2.625)

0.976

CTL-NK score

0–1 vs. 2–5

0.357 (0.154–0.825)

0.016

0.451 (0.168–1.212)

0.114

  1. p values were calculated by Cox proportional hazards model
  2. aInclude metaplastic carcinoma and carcinoma with apocrine differentiation
  3. HR, hazard ratio; CI, confidence interval; Yrs, years; IC-NST, invasive carcinoma of no special type; LVI, lymphovascular invasion; DCIS, ductal carcinoma in situ; TIL, tumor-infiltrating lymphocyte; DCIS, ductal carcinoma in situ; GNLY, granulysin; GZMB, granzyme B; CTL, cytotoxic T lymphocyte; NK, natural killer